Atopic dermatitis (AD) is the most common inflammatory skin disease, but treatment options for moderate-to-severe disease are limited. Ustekinumab is an IL-12/IL-23p40 antagonist that suppresses Th1, Th17 and Th22 activation, commonly used for psoriasis patients. We sought to assess efficacy and safety of ustekinumab in patients with moderate-to-severe AD. In this phase II, double-blind, placebo-controlled study, 33 patients with moderate-to-severe AD were randomly assigned to either ustekinumab (n=16) or placebo (n=17), with subsequent crossover at 16 weeks, and last dose at 32 weeks. Background therapy with mild topical steroids was allowed to promote retention. Study endpoints included clinical (SCORAD50) and biopsy-based measures of tissue structure and inflammation, using protein and gene expression studies. The ustekinumab group achieved higher SCORAD50 responses at 12, 16 (the primary endpoint) and 20 weeks compared to placebo, but the difference between groups was not significant. The AD molecular profile/transcriptome showed early robust gene modulation, with sustained further improvements until 32 weeks in the initial ustekinumab group. Distinct and more robust modulation of Th1, Th17 and Th22 but also Th2-related AD genes was seen after 4 weeks of ustekinumab treat- show a partial or no effect. 17,18 Importantly, controlled trials are lacking.
| Study design
This was a phase II, randomized, placebo-controlled, double-blinded single-centre study (clinicaltrials.gov: NCT01806662) to investigate safety and efficacy of ustekinumab treatment in moderate-to-severe AD patients. Patients underwent 1:1 randomization using a computergenerated subject randomization table by an unblinded pharmacist.
Subjects received subcutaneous ustekinumab or placebo at weeks 0, 4 and 16 with a crossover to the other agent (either ustekinumab or placebo) at weeks 16, 20 and 32 (Fig. 1a ) to ensure patient retention. Thus, each patient received three doses of ustekinumab during the study, as on week 16, each patient received two injections (both ustekinumab and placebo)-one to complete the first part of the study and a second reflecting the crossover design. Dosing of ustekinumab followed the recommendations for psoriasis, namely 45 and 90 mg per injection for patients weighing ≤100 or >100 kg, respectively.
Background therapy of triamcinolone 0.025% cream BID was given to the patients starting at week 0 to promote patient retention. The average amount of GCS cream given to each patient was 1.53 (±0.83) and 1.19 (±0.83) pound jars in the placebo-ustekinumab and in the ustekinumab-placebo group, respectively. Although patients in the initial placebo group requested a higher number of GCS jars, differences were not statistically significant among treatment arms.
The primary and secondary clinical endpoints were a 50% or greater percentage decrease from baseline objective SCORAD (SCORing of AD) at week 16 or 32, respectively. Patients were evaluated for clinical responses and for quality of life every 2-4 weeks until week 40, using SCORAD and DLQI (Dermatology Life Quality Index), respectively.
A follow-up phone call at week 52 concluded the study. After week 52, patients who achieved a SCORAD50 response at any time point during the study were then qualified to receive another ustekinumab dose to participate in a 12-week open-label extension phase.
Subjects that withdrew from the study before completing 4 weeks (and a lesional biopsy at 4 weeks) were considered treatment failures. For subjects who dropped out after this time point, the last visit was considered as our primary endpoint (last observation carried forward). A subgroup analysis on responses to background therapy in the placebo group (until week 16) has been reported in a separate publication. 19 The study was conducted in accordance with current United All participants provided written informed consent under an IRBapproved protocol.
T A B L E 1 Baseline characteristics of the study population

| Immunohistochemistry
Immunohistochemistry (IHC) stainings were performed on frozen cryostat tissue sections using purified mouse anti-human mAbs, as previously described. 20, 21 Epidermal thickness was quantified using computer-assisted image analysis software (ImageJ 1.42; National
Institutes of Health, Bethesda, MD, USA).
| Quantitative real-time PCR and genearray analysis
RNA was extracted, followed by hybridization to Affymetrix Human U133Plus 2.0 gene arrays (Affymetrix, Santa Clara, CA, USA) or quantitative RT-PCR/TLDA, as previously described (Table S2 ). 
| RESULTS
| Patients
The design of this placebo-controlled crossover study is shown in Fig. 1a . A total of 35 patients with moderate-to-severe AD were screened, and 33 enrolled in a 1:1 randomization in two treatment arms (Table S3) . One patient from the placebo-ustekinumab group was retrospectively excluded from analyses due to initial misdiagnosis.
One patient was excluded from tissue analyses due to quality control issues, and one patient dropped out already by week 2 and was therefore not included in tissue analyses. Demographics and baseline characteristics were not different between groups (ustekinumab-placebo and placebo-ustekinumab; Table 1; Table S1 ). A total of 27 patients Thus, SCORAD50 data in both groups suggest that the response was optimal 8 weeks after administration of a ustekinumab dose. In addition, SCORAD75 responses showed a trend of increased treatment responses beginning with week 20 in the initial ustekinumab group, with waning effects after week 28 (Fig. S1c) . The initial placebo group, by contrast, showed low and relatively stable responses until week 32, and a surge in responses thereafter (Fig. S1c) . These data, although not statistically significant, suggest that a SCORAD75 response can be achieved by a subset of patients after three ustekinumab injections.
| Tissue responses to treatment
To further characterize ustekinumab treatment responses, we assessed lesional and non-lesional biopsies from patients, and stratified for both clinical and histological responses. Clinical response was defined by our primary endpoint, SCORAD50 response at 16 weeks, and histological response was defined as a decrease in epidermal thickness (Fig. S2a) as well as a resolution of K16 protein staining (Fig. S2b) 
| Gene profiling shows more rapid and sustained responses with ustekinumab
Gene arrays were performed to define the AD transcriptome (differentially expressed genes/DEGs in lesional versus non-lesional skin at baseline; criteria of FCH>1.5, FDR<0.05 ; Table S5 ), 21, 24 and to assess the effect of ustekinumab on the transcriptome. The heatmap in Fig. 2a shows mean expression levels of transcriptomic genes in both treatment arms. While baseline/week 0 levels were similar among groups, a strong treatment effect was observed only in the ustekinumab group by 4 weeks, while the placebo group largely remained stable. Improvements in the transcriptome (red-to-blue and blue-to-red transitions) at 20 weeks, and even more so at 32 weeks, were much more evident in the ustekinumab-placebo group, again suggesting a long-term therapeutic effect of ustekinumab. We also assessed the number of transcriptome genes that were significantly modulated from baseline over the course of the study, as shown in Fig. 2b -e. At 4 weeks, 117 DEGs from baseline were noted in the ustekinumab arm (Fig. 2b) , compared to only 14 DEGs in the placebo group. While this difference was lost by 16 and 20 weeks of treatment (Fig. 2c,d) , at 32 weeks, most genes (424/780) were differentially expressed in the ustekinumab-placebo group, but only 99 in the placebo-ustekinumab arm (Fig. 2e) . Importantly, differentially expressed genes between the two groups showed little overlap at 16 weeks, suggesting distinct treatment effects by ustekinumab and by "placebo," that is background triamcinolone treatment only.
| Immune gene subset profiling
As AD is a cytokine-mediated disease, 8 we assessed changes from baseline in a previously defined immune gene subset in lesional and non-lesional skin (criteria: FCH>2 and P<.05; Fig. S3 ). Stronger and more significant decreases were seen in mRNA expressions at 4 weeks in the ustekinumab group. These included general inflammation, T cell, Th2 and Th17 markers (MMP12, CX3CR1, CCL19, CCL17, PI3/elafin, lipocalin 2/LCN2). Sustained significant decreases in immune genes at 32 weeks were more prominent in the ustekinumab-placebo group, including markers of general inflammation (MMP12), T cells (GZMB), IL-22/IL-17-induced S100As, Th2-attracting chemokines (CCL17, CCL18), Th1 (OASL) and Th17-related products (CXCL1).
| qRT-PCR assessments
To validate microarray findings, and to evaluate primary Th1, Th2, Th17, Th22 cytokines and terminal differentiation markers, which are often below detection levels on gene arrays, 25 
| DISCUSSION
We assessed efficacy and safety of ustekinumab in patients with moderate-to-severe AD, with continuous background topical steroid therapy in both treatment arms to enhance patient retention. This study also presents several limitations: (i) a clear limitation is that the study has been designed a few years ago without knowledge of pharmacokinetics or drug durability in AD patients, and therefore, psoriasis dosing intervals 31 were chosen; (ii) we also failed to appreciate the magnitude of systemic inflammation in patients with moderate-to-severe AD, which is significantly larger than in psoriasis, as evidenced by the observation that T cells, particularly in the peripheral blood, show much stronger signs of activation in AD than in psoriasis as assessed by ICOS expression, a marker of T-cell activation. 32, 33 This hyperactivation in patients with moderateto-severe AD might lead to accelerated clearance of target-bound ustekinumab and/or the need for either higher or more frequent dosing of ustekinumab in this disease. This is also supported by a recent report of a patient with severe, recalcitrant AD that has been treated effectively with much shorter intervals of ustekinumab given every 8 weeks 16 ; (iii) the treatment effect might be partially masked due to use of background topical GCS. In this study, treatment with a class VI low-potency GCS formulation led to profound effects in the placebo, and possibly also in the treatment arm, an effect that is particularly evident after the 4 weeks time point in placebo-treated patients. For this reason, we advocate to avoid "add-on" topical GCS in AD trials, as even after several weeks of application, topical GCS do not lead to a stable disease phenotype, as recently described. 19 Nevertheless, although profoundly improving disease activity as measured by SCORAD, our data show that the use of background GCS in the placebo arm modulated different genes than with ustekinumab treatment. This was best visible at 16 weeks, when despite small differences observed in clinical disease activity between the two treatment arms, only few DEGs were shared between the two groups. We must also point out that although it becomes increasingly evident that monotherapy trials with systemic medications for moderate-to-severe AD can be successfully conducted for a few months and are able to highlight the unique benefits of the study drug, 34, 35 our trial was designed at a time when it seemed impossible to keep patients with significant disease on placebo alone; (iv) another weakness of this study was clearly that at 16 weeks, both treatment arms received the active drug, so the primary endpoint is not able to assess for the last dose of ustekinumab in the ustekinumabplacebo arm. Indeed, at 20 weeks (4 weeks from last dose), we can detect the maximal clinical efficacy as well as major molecular and cellular suppression with ustekinumab; (v) additionally, while the crossover design is helpful with patient retention, it possibly blurs the ustekinumab effects in the second half of the study; (vi) another limitation of this study is that both Th1 and Th17 immune axes are inhibited by ustekinumab, which prevents individual assessment of their potential role in the disease phenotype. 5, 7, [36] [37] [38] Th1 responses have long been described as present particularly in patients with chronic AD, 37, 39 while increased Th17 responses were found in acute AD. 40, 41 Stronger IL-23/Th17 skewing was described in intrinsic AD compared to extrinsic AD patients. 42 Noda et al. 36 have recently
showed that the Th17 axis is strongly activated in Asian AD patients, suggesting that this phenotype harbours some psoriasis-like features. Thus, ustekinumab might be more effective in patients with intrinsic or Asian AD, which favours more personalized treatment approaches for different AD phenotypes.
Unlike psoriasis that is Th17-centred, recent findings suggest that the AD phenotype cannot be explained by a single cytokine pathway. differentiation (R-S), general inflammation (T), innate immunity genes (U) are depicted; red and blue asterisks denote significant changes from baseline, and orange asterisks denote significant differences in changes from baseline between treatment arms; mean ± SEM; *P < 0.05; **P < 0.01; ***P < 0.001 Table S1 Individual demographic data of the atopic dermatitis patients enrolled in this study, including IgE status (intrinsic < 200 kU/L), race, gender, age, total serum IgE (U/mL), blood eosinophils/EOS (%) and SCORAD at baseline 
